USE OF HUMAN NOT1 AND NOT1A ORPHAN RECEPTORS

The use of NOT1 or NOT1 a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions. L'invention porte sur l'uti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CAIRNS, WILLIAM, JOHN, HOLDER, JULIE, CAROLINE, PATEL, LISA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The use of NOT1 or NOT1 a polypeptides and polynucleotides in the design of protocols for the treatment of obesity, insulin resistance, type 2 diabetes, impaired glucose tolerance, cachexia or liposarcoma, among others, and diagnostic assays for such conditions. L'invention porte sur l'utilisation de polypeptides et polynucléotides NOT1 ou NOT1A pour la conception de protocoles en vue notamment du traitement de l'obésité, de la résistance à l'insuline, du diabète de type 2, d'une mauvaise tolérance au glucose, de la cachexie, des liposarcomes, et pour l'élaboration d'essais diagnostiques.